Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Travoprost
Drug ID BADD_D02265
Description Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152].
Indications and Usage Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Marketing Status Prescription; Discontinued
ATC Code S01EE04
DrugBank ID DB00287
KEGG ID D01964
MeSH ID D000069557
PubChem ID 5282226
TTD Drug ID D09CZA
NDC Product Code 54893-0020; 40016-006; 0078-0946; 82231-114; 45542-1162; 38779-3063; 64181-0028; 63629-8839; 65035-131; 65129-1207; 61556-040; 0781-6185; 24002-0022; 68245-0003; 63190-0350; 60505-0593; 63629-8840; 55359-540
Synonyms Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221
Chemical Information
Molecular Formula C26H35F3O6
CAS Registry Number 157283-68-6
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotony of eye06.08.03.0040.001187%Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intraocular pressure decreased13.07.04.0060.001187%Not Available
Intraocular pressure increased13.07.04.0020.007518%Not Available
Iridocyclitis06.04.03.001--Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.0040.001187%
Macular degeneration06.09.03.001--Not Available
Macular oedema06.04.06.0050.001187%Not Available
Malaise08.01.01.003--
Meibomianitis06.04.04.008--Not Available
Memory impairment19.20.01.003; 17.03.02.0030.001583%
Metrorrhagia21.01.01.006--Not Available
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
Nasal congestion22.04.04.0010.001187%
Nasal dryness22.04.03.002--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.0020.001583%Not Available
Nausea07.01.07.001--
Neoplasm malignant16.16.01.0010.000310%Not Available
Nervous system disorder17.02.10.001--Not Available
Ocular hyperaemia06.04.05.0040.017411%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 8 Pages